Most U.S. neurologists are willing to use the PET imaging agent Amyvid to assess patients for Alzheimer's disease if the scan will be covered by health insurance, according to findings from a study published in the Journal of Alzheimer's Disease. Most of the respondents planning to use the agent said they would do so as part of an adjunctive diagnostic test to rule out or confirm the disease, the survey found. Ninety-two percent of respondents said that before patients undergo the test, they should be informed of how the results will be interpreted. The findings indicate experts in the field see a clinical value in using the test, researchers said.
Published in Brief: